National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Bosutinib is indicated for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukaemia (Ph+ CML) previously treated with one or more tyrosine kinase inhibitor(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

Rapid Review

Commenced Completed Outcome
09/08/2013 18/09/2013 At the current price a full HTA would be required.

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.